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Abstract
Background: Glycemic variability (GV) creates challenges to glycemic control and may be an independent marker
for unfavorable outcome in management of patients with diabetes. This study was designed to investigate the
effect of excessive visit-to-visit GV on the progression of endothelial and renal dysfunction in patients with type 2
diabetes mellitus (T2DM).
Methods: Two hundred and thirty nine patients with T2DM, who were recruited from outpatient, completed
48-month follow-up visit. Visit-to-visit GV was calculated by the standard deviation (SD) and coefficient of variation
(CV) of serially measured HbA1c and fasting plasma glucose (FPG). Endothelial and renal function was assessed at
baseline and end of follow-up.
Results: At end of follow-up, brachial flow-mediated dilation (FMD), nitric oxide (NO), creatinine-based estimated
glomeruar filtration rate (eGFR-Cr), and cystatin C-based estimated glomeruar filtration rate (eGFR-Cys C) increased,
and endothelin-1 and urine albumin/creatinine ratio (ACR) declined as compared with baseline in overall (P < 0.05).
The increment of FMD, NO, eGFR-Cr, and eGFR-Cys C and the decrement of endothelin-1 and ACR in first tertile
group were significantly greater than those in third tertile group classified by tertile of either SD of HbA1c or SD of
FPG. Change percentage of FMD, NO, eGFR-Cr, and eGFR-Cys C were positively, and change percentage of
endothelin-1 and ACR were negatively correlated with SDs of HbA1c and FPG, and CVs of HbA1c FPG (P < 0.01,
respectively). After adjusted for mean HbA1c, mean FPG, baseline demographic, and clinical characteristics, SD of
HbA1c and SD of FPG were always statistically correlated with change percentage of FMD, NO, endothelin-1, ACR,
eGFR-Cr, and eGFR-Cys C.
Conclusion: Excessive visit-to-visit GV independently deteriorates the progression of endothelial and renal
dysfunction in patients with T2DM.
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Background
It is well accepted that type 2 diabetes mellitus (T2DM) is
a progressive multisystemic disease accompanied by endo-
thelial [1, 2] and renal dysfunction [3].
Endothelial dysfunction is regarded as a crucial factor
in the pathogenesis of vascular disease in diabetes melli-
tus [4–6]. It is broadly defined as an imbalance between
endothelium-dependent vasodilatation and vasoconstric-
tion as well as antithrombotic and prothrombotic factors
[7]. Evidences have demonstrated that endothelial dys-
function is closely associated with the development of
diabetic microvascular disease including nephropathy
and retinopathy in T2DM [8].
Renal dysfunction is one of serious and common clin-
ical microvascular complications in patients with T2DM
[3]. It can lead to end-stage renal failure. Glomerular fil-
tration rate (GFR) and urinary albumin excretion (UAE)
are both recognized as available indexes of renal func-
tion in individuals with or without diabetes [9, 10]. A re-
markable meta-analysis, included 45 cohorts and a total
of 1,555,332 participants, confirmed that each GFR and
UAE is independent predictor of renal outcomes [11].
To reduce the risk of diabetic complications, effective
glycemic control is a critical goal of diabetes manage-
ment [12–15]. But a growing body of evidence reveals
that glycemic variability (GV) creates challenges to gly-
cemic control and may be an independent marker for
unfavorable outcome in management of patients with
diabetes in recent years [12–15]. Moreover, excessive
long-term fluctuation, assessed using visit-to-visity GV,
in the glycemic control was demonstrated to cause poor
outcomes such as macro- and microvascular events and
all cause mortality in T2DM patients with the intensive
glucose treatment [12]. However, very little information
is currently available on correlation between long-term
GV, such as visit-to-visit GV, and the progression of
endothelial and renal dysfunction in patients with T2DM.
The aim of this study was to investigate the association
of excessive visit-to-visit GV with the progression of endo-
thelial and renal dysfunction in patients with T2DM.
Methods
Study design and patients
From August 2007, 264 patients with T2DM aged
55 years or older were recruited from outpatient of
Cardio-Cerebrovascular Control and Research Center,
Institute of Basic Medicine, Shandong Academy of Med-
ical Sciences, China. Patients were ineligible if, in the
opinion of the investigator, they met any of the following
exclusion criteria: severe hyperglycemia (FPG > 400 mg/dL
or 22.2 mmol/L); recent acute serious events such
as diabetic ketoacidosis, hyperglycemic hyperosmolar
state, severe hypertension (SBP > 170 mmHg and/or
DBP > 100 mmHg), secondary hypertension, cerebral
stroke, and myocardial infarction in the previous 3 months;
heart failure; hemodialysis; abnormal liver enzymes (as-
partate aminotransferase and alanine aminotrasferase > 3
times than upper normal range); difficulty with providing
informed consent; current participation in another clinical
trial. Follow-up visit was conducted every 3 months after
baseline visit. All eligible recruited patients were asked to
complete 48-month follow-up visit. Guidance of diabetic
diet, hypoglycemic therapy, regular exercise, mental ad-
justment (such as set up confidence to defeat the disease,
keep up a positive attitude and optimistic mood.), and
self-monitoring were recommended by investigators or
specialist doctors in diabetes at each follow-up visit. Eli-
gible patients were asked to strictly execute the guidance.
Hypoglycemic agent included metformin, gliclazide, other
sulfonylurea, thiazolidinedione, acarbose, glinide, and
insulin. HbA1c and fasting plasma glucose (FPG) were
monitored at baseline and each follow-up visit in all pa-
tients. Hypoglycemia was defined as Zoungas et al. [16]
described, namely, a blood glucose level of less than
2.8 mmol/L (50 mg/dL) or the presence of typical
symptoms and signs of hypoglycemia without other ap-
parent cause. Severe hypoglycemic episodes were reported
with a full description of the event at the time of their oc-
currence during follow-up visit. Endothelial function
[assessed by brachial flow-mediated dilation (FMD), nitric
oxide (NO) and endothelin-1 (ET-1)] and renal function
[assessed by urinary albumin/creatinine ratio (ACR), esti-
mated GFR based on creatinine (eGFR-Cr) and estimated
GFR based on cystatin C (eGFR-Cys C)] were evaluated at
baseline and end of follow-up visit.
This study confirmed to good clinical practice guidelines
and was conducted in compliance with the “Declaration
of Helsinki”. The Research Ethics Committee of Institute
of Basic Medicine, Shandong Academy of Medical Sciences
approved this study, and written informed consent was
obtained from each participant.
Glycemic parameter measurements and definition of
visit-to-visit glycemic variability
HbA1c (%) was detected using the DCA 2000 analyzer
(Miles, Diagnostic Division, Elkhart, IN). Finger-sticks
from the patients were collected by trained nurses. The
DCA 2000 instrument, base on an immunochemical
technique, has been proposed for the rapid and simple
evaluation of HbA1c. The accuracy and reproducibility
of this HbA1c measurement has been certificated and
used in clinical practice, as revealed by its good preci-
sion and good agreement with the reference system
(Diamat™ using high performance liquid chromatography
method) [17, 18]. Fasting plasma glucose (FPG) was
measured by routine enzymatic laboratory methods
using a Hitachi 7600 automated biochemical analyzer
(Hitachi, Ltd, Tokyo, Japan). Mean, standard deviation
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(SD), and coefficient of variation (CV) of each patient’s
serial HbA1c or FPG throughout follow-up period were
calculated. CV = SD/mean × 100 (%). Visit-to-visit GV
was assessed using both SD and CV of HbA1c and FPG.
Brachial flow-mediated dilation measurement
Brachial flow-mediated dilation (FMD) of reactive
hyperemia is known to be endothelium-dependent and a
widely accepted noninvasively clinical method for asses-
sing systemic endothelial functions [19, 20]. Brachial
FMD has been demonstrated to be markedly abnormal
in patients with diabetes and those with diabetic
microalbuminuria [21, 22]. In the present study, FMD
was evaluated from 08:00 to 09:30 in a quiet and
temperature-controlled room (20–25 °C) according to
the method described by Thijssen et al. [19]. Participants
were demanded to fast for 12 h and discontinue smo-
king, alcohol, caffeine, tea, anti-histamine, vasoactive
medications (including nitrates, angiotensin antagonists,
calcium antagonists, and angiotensin-converting enzyme
inhibitors), and anti-inflammatory medications for 24 h
before measurement performed. After at least 10 min of
lying in the supine position, the right brachial artery was
scanned over a longitudinal section 3 to 5 cm above the
elbow using high-resolution ultrasound (Vivid i, GE
Medical Systems Ultrasound Israel Ltd.) with a handheld
7.5-MHz transducer (7.5-SPC mechanic sector trans-
ducer; GE Medical Systems Ultrasound Israel Ltd.) at
rest and in response to increased flow. Increased flow
was induced by inflation of a pneumatic tourniquet
placed around the forearm to a pressure of 250 mmHg
for 5 min, followed by a release. Arterial diameter was
measured using M-mode echography during the end-
diastolic phase at a fixed distance from an anatomic
marker at baseline and 60, 90, and 120 s after cuff defla-
tion. The maximum diameter response from the 3 mea-
surements was used to derive FMD. FMD was calculated
with the formula: [(maximum diameter – baseline dia-
meter)/baseline diameter] × 100 %. Measurements were
performed by one experienced ultrasonographer, images
were recorded on video and later analyzed by the same
trained reader who was blinded to angiographic and
clinical data. In order to determine the reliability of the
measurements, 14 patients were randomly selected for
repeated assessment. The intra-observer coefficient of
variation for FMD was 3.02 ± 1.64 %.
Nitric oxide measurement
Nitric oxide (NO) is a crucial endothelium-derived
molecule for vascular relaxation. It has been found that
disturbances in NO bio-availability can cause endothelial
dysfunction, leading to increased susceptibility to hyper-
tension, diabetes mellitus and atherosclerotic lesion pro-
gression [23, 24].
Serum concentration of NO was measured indirectly
by the quantification of nitrite (NO2
−), a stable metabolite
of NO, using Griess assay [25]. Briefly, 100 μl of serum
were transferred to a flat-bottom 96-well microtiter
plate, then mixed with 50 μl of 2 % sulfanilamide in 5 %
HCl solution and 50 μl of 0.1 % N-(1-Naphtyl) ethylen-
diamine in water sequentially. 100 μl vanadium chloride
III 0.8 % was added to each sample and incubate at 37 °C
for one hour to reduce nitrate to nitrite. The concentra-
tion of nitrite was determined by measuring optical den-
sity using an ELISA-reader (Poweam Medical Systems
Co., Ltd.) in 540 nm. All reagents were purchased from
Sigma (St. Louis, MO, USA). Samples were measured in
duplicate and the mean was used for further analyze.
Endothelin-1 measurement
Plasma concentrations of endothelin-1 (ET-1), an impor-
tant member of the endothelin family and a marker of
endothelial injury, were tested using enzyme-linked
immunosorbent assay (ELISA) kits following the man-
ufacturer’s instructions (Bender MedSystems, Vienna,
Austria). Minimum detectable concentration was less
than 1.0 pg/mL. Intra-assay and inter-assay coefficients
of variation were less than 5 %. All samples were mea-
sured in duplicate.
Evaluation of estimated glomerular filtration rate
eGFR-Cr and eGFR-Cys C have the most commonly
been used to evaluate renal function. Equations of
eGFR combining serum creatinine and cystatin C have
been indicated to further improve the precision of
GFR estimates [26, 27].
Serum concentration of Cr was determined by Jaffe’s
kinetic method using a Hitachi 7600 automated bioche-
mical analyzer. The normal reference range was 50–110
μmol/L. GFR estimation from serum Cr was made using
the CKD-EPI equation is: eGFR-Cr = 141 ×min (SCr/k,
1)α ×max (SCr/k, 1)-1.209 × 0.993Age (×1.018, if female),
which is considered the best in Chinese population [28].
In the equation, k is 0.7 for females and 0.9 for males, α
is −0.329 for females and −0.411 for males, “min” indi-
cates the lesser of SCr/k or 1, and “max” indicates the
greater of SCr/k or 1.
Cys C was determined by latex enhanced immunotur-
bidimetric assay (Mike Biotechnology Co., Ltd., Sichuan,
China). Variation was less than 4 % for intra-assay and
6 % for interassay. GFR was carried out using Hoek for-
mula: eGFR-Cys C = −4.32 + 80.35 × 1/CysC in mg/L [29].
Evaluation of urinary albumin excretion
Albuminuria has been extensively recommended as a
major prognostic indicator in individuals with diabetes
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[30, 31]. UAE was determined on the basis of the urinary
ACR. Early morning first void sterile urinary spot sam-
ples were collected during the health examination. Urin-
ary albumin and creatinine levels were determined by
immunonephelometry and the Jaffe reaction-rate
method (Hitachi 7600 automated biochemical analyzer),
respectively. And then, ACR was calculated.
Clinical laboratory measurements
Total cholesterol (TCHO), triglycerides (TG), high-
density lipoprotein cholesterol (HDL-c), and low-density
lipoprotein cholesterol (LDL-c) were measured by rou-
tine enzymatic laboratory methods using a Hitachi 7600
automated biochemical analyzer (Hitachi, Ltd, Tokyo,
Japan) at baseline and at annual follow-up visit.
Statistical methods
Statistical analysis was performed using the SPSS 17.0
statistical software (SPSS 17.0 for Windows, Chicago,
IL, USA). Continuous values were expressed as means
with SD. Normality of data were evaluated using
Kolmogorov-Smirnov test. If not normally distributed,
the data were expressed as median with inter-quartile
range (IQR, the range between the 25th and 75th per-
centile). Categorical data were expressed as numbers
(percentages). Change percentage was used to represent
the changes of FMD, NO, ET-1, ACR, eGFR-Cr, and
eGFR-Cys C throughout follow-up period. Change per-
centage was calculated as follows: [(value at end of
follow-up – value at baseline)/value at baseline] × 100 %.
Accordance with tertile of mean SD of HbA1c, patients
were classified into three groups, namely, first tertile
group, second tertile group, and third tertile group.
Meanwhile, patients were also divided into first tertile
group, second tertile group, and third tertile group by
tertile of mean SD of FPG. Comparisons of continuous
values among groups were performed using one way
analysis of variance (ANOVA) with Bonferroni proce-
dure or Kruskal-Wallis test depending on the normality
of data. Categorical data were compared by Chi-square
test. According to the normality of data, Student’s paired
t-test or Mann–Whitney test was used to detect the dif-
ferences in FMD, NO, ET-1, ACR, eGFR-Cr, and eGFR-
Cys C between baseline and end of follow-up. Pearson
or Spearman correlation coefficient was used to measure
the strength of association between variables. Backward
stepwise multiple linear regression analysis was per-
formed to examine the independently relationships of
change percentage of FMD, NO, ET-1, ACR, eGFR-Cr,
and eGFR-Cys C with visit-to-visit GV and other vari-
ables. In the model, 0.05 was used as cutoff for retention
and elimination of variables. Value of two-tailed P < 0.05
was considered statistically significant.
Results
Baseline demographic and clinical characteristics
Figure 1 summarizes the flow diagram of the study.
Among 264 patients, 25 patients were excluded for the
following reasons: 4 died, 8 withdrew, and 13 failed to
complete the study. Finally, 239 participants completed
48-month follow-up visit and were included and used
for further analysis.
Baseline demographic and clinical characteristics of
participants are summarized in Table 1. There were no
Fig. 1 Flow diagram of the study
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statistically significant differences among groups classi-
fied by tertile of SD of HbA1c and tertile of SD of FPG
with respect to clinical and biochemical variables.
Baseline variables of renal and vascular endothelial function
Table 2 shows the baseline variables of renal and vascular
endothelial function. ET-1 in third tertile group classified
by tertile of SD of HbA1c was significant higher than that
in first and second tertile group (P < 0.05). Compared with
first tertile group classified by tertile of SD of FPG, eGFR-
Cys C was lower in third tertile group (P < 0.05).
HbA1c and FPG profiles and severe hypoglycemic episodes
during follow-up period
Table 3 reveals the comparison of HbA1c and FPG pro-
files and episodes of severe hypoglycemia during follow-
up period among three groups classified by the tertile of
SD of HbA1c and by the tertile of SD of FPG.
We compared HbA1c and FPG profiles and episodes
of severe hypoglycemia among three groups classified by
tertile of SD of HbA1c. SD and CV of FPG and episodes
of severe hypoglycemia in third tertile group were higher
than those in first and second tertile group (P < 0.05).
Table 1 Baseline demographic and clinical characteristics according to tertiles of SD of HbA1c and SD of FPG
Classified by tertile of SD of HbA1c Classified by tertile of SD of FPG
First tertile
group (n = 79)
Second tertile
group (n = 80)
Third tertile
group (n = 80)
P value First tertile
group (n = 79)
Second tertile
group (n = 80)
Third tertile
group (n = 80)
P value
Age (year)a 65.97 ± 5.52 64.36 ± 7.30 64.88 ± 5.74 0.253 65.27 ± 6.09 64.71 ± 6.08 65.23 ± 6.62 0.825
Sex, female (%)b 36 (45.57) 42 (52.50) 47 (58.75) 0.252 41 (50.00) 47 (59.49) 37 (47.44) 0.279
BMI (kg/m2)a 24.43 ± 2.94 23.58 ± 2.71 23.79 ± 2.81 0.147 23.89 ± 2.89 23.44 ± 2.75 24.46 ± 2.79 0.074
SBP (mm Hg)a 152.92 ± 11.85 153.01 ± 8.71 156.02 ± 8.99 0.083 152.35 ± 8.16 153.56 ± 9.70 156.03 ± 11.61 0.061
DBP (mm Hg)a 83.68 ± 9.54 80.81 ± 7.73 82.92 ± 7.08 0.073 83.06 ± 8.34 82.38 ± 7.35 81.96 ± 8.99 0.701
Heart rate (bpm)a 74.82 ± 9.65 76.01 ± 9.09 74.34 ± 8.89 0.498 74.65 ± 10.78 75.30 ± 7.30 75.23 ± 9.31 0.888
Duration of diabetes (years)c 3.00 (2.85, 3.25) 3.00 (2.85, 3.27) 3.00 (2.82, 3.33) 0.905 3.00 (2.90, 3.35) 3.00 (2.69, 3.13) 3.00 (2.93, 3.19) 0.342
Current smoking, n (%)b 8 (10.13) 9 (11.25) 7 (8.75) 0.871 8 (9.76) 8 (10.13) 8 (10.26) 0.994
Current drinking, n (%)b 5 (6.33) 6 (7.50) 5 (6.25) 0.940 7 (8.54) 3 (3.80) 6 (7.69) 0.442
Hypertension history, n (%)b 62 (78.48) 60 (75.00) 65 (81.25) 0.631 64 (78.05) 61 (77.22) 62 (79.49) 0.941
FPG (mmol/L)a 9.80 ± 1.50 9.80 ± 1.57 10.14 ± 1.54 0.269 9.97 ± 1.43 9.99 ± 1.46 9.78 ± 1.72 0.625
HbA1c (%)a 10.01 ± 2.00 10.17 ± 1.53 10.62 ± 1.34 0.061 10.21 ± 1.44 10.19 ± 1.76 10.40 ± 1.77 0.684
TCHO (mmol/L)a 5.10 ± 0.99 5.36 ± 0.96 5.39 ± 1.00 0.127 5.41 ± 0.91 5.27 ± 0.96 5.18 ± 1.08 0.332
TG (mmol/L)a 1.89 ± 1.11 1.61 ± 0.84 1.73 ± 1.01 0.200 1.65 ± 0.88 1.65 ± 0.88 1.92 ± 1.18 0.139
HDL-c (mmol/L)a 1.37 ± 0.45 1.41 ± 0.48 1.38 ± 0.50 0.893 1.38 ± 0.50 1.36 ± 0.41 1.42 ± 0.52 0.768
LDL-c (mmol/L)a 3.35 ± 1.15 3.63 ± 1.11 3.67 ± 1.21 0.167 3.70 ± 1.08 3.58 ± 1.03 3.38 ± 1.33 0.215
Hypoglycemic agents, n (%)b
Metformin 73 (92.41) 72 (90.00) 75 (93.75) 0.675 74 (90.24) 74 (93.67) 72 (92.31) 0.720
Gliclazide 39 (49.37) 34 (42.50) 35 (43.75) 0.653 37 (45.12) 36 (45.57) 35 (44.87) 0.996
Other sulfonylurea 24 (30.38) 21 (26.25) 22 (27.50) 0.839 22 (26.83) 18 (22.78) 27 (34.62) 0.245
Thiazolidinedione 7 (8.86) 5 (6.25) 8 (10.00) 0.681 11 (13.41) 4 (5.06) 5 (6.41) 0.120
Acarbose 15 (18.99) 15 (18.75) 11 (13.75) 0.613 19 (23.17) 12 (15.19) 10 (12.82) 0.189
Glinide 4 (5.06) 4 (5.00) 3 (3.75) 0.905 5 (6.10) 4 (5.06) 2 (2.56) 0.551
Insulin 9 (11.39) 7 (8.75) 7 (8.75) 0.809 8 (9.76) 8 (10.13) 7 (8.97) 0.969
Other drugs, n (%)b
Antihypertension drug 57 (72.15) 56 (70.00) 63 (79.63) 0.425 58 (70.73) 58 (73.42) 60 (76.92) 0.673
Aspirin 56 (70.89) 49 (61.25) 43 (53.75) 0.084 51 (62.20) 47 (59.49) 50 (64.10) 0.836
Statins 11 (13.92) 13 (16.25) 11 (13.75) 0.883 12 (14.63) 12 (15.19) 11 (14.10) 0.982
Results are means ± SDs or medians (25th, 75th percentiles) for continuous variables and numbers (percentages) for categorical variables
SD standard deviation, HbA1c hemoglobin A1c, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, FPG fasting plasma glucose,
TCHO total cholesterol, TG triglycerides, HDL-c high-density lipoprotein cholesterol, LDL-c low-density lipoprotein cholesterol
acompared using ANOVA with Bonferroni procedure
bcompared using Chi-square test
ccompared using Kruskal-Wallis test
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CV of FPG and episodes of severe hypoglycemia in sec-
ond tertile group were higher than those in first tertile
group (P < 0.05).
HbA1c and FPG profiles and episodes of severe hypo-
glycemia were compared among three groups classified
by tertile of SD of FPG. SD and CV of HbA1c in second
and third tertile groups were higher than those in first
tertile group (P < 0.05).
Vascular parameters and glycemic variability throughout
follow-up period
Table 4 demonstrates the change percentage of FMD,
NO, and ET-1 from baseline to end of follow-up in overall.
In all patients, FMD and NO were significantly increased,
and ET-1 was markedly declined at end of follow-up
compared to baseline (P < 0.05).
As with patients classified by tertile of SD of HbA1c,
FMD and NO were significant increment in first tertile
group (P < 0.05), and were significant decrement in third
tertile group (P < 0.05). ET-1 was significant decrement
in first tertile group (P < 0.05). Increased percentage of
FMD and NO and decreased percentage of ET-1 in first
tertile group were obviously greater than those in second
and third tertile groups (P < 0.05). Increased percentage
of FMD and NO and decreased percentage of ET-1 in
second tertile group were greater than those in third
tertile groups (P < 0.05).
As with patients grouped by tertile of SD of HbA1c,
increased percentage of FMD in first and second
Table 2 Baseline variables of renal and vascular endothelial function according to tertiles of SD of HbA1c and SD of FPG
Classified by tertile of SD of HbA1c Classified by tertile of SD of FPG
First tertile
group (n = 79)
Second tertile
group (n = 80)
Third tertile
group (n = 80)
P value First tertile
group (n = 79)
Second tertile
group (n = 80)
Third tertile
group (n = 80)
P value
ACR (mg/mmol)a 1.60 (1.40, 2.25) 1.57 (1.10, 2.72) 1.78 (1.20, 2.52) 0.792 1.60 (1.30, 2.14) 1.58 (1.21, 2.50) 1.80 (1.30, 2.80) 0.306
Creatintine (mg/dl)b 0.73 ± 0.13 0.74 ± 0.13 0.76 ± 0.13 0.429 0.72 ± 0.12 0.74 ± 0.13 0.77 ± 0.14 0.097
Cystatin C (mg/L)b 0.78 ± 0.16 0.83 ± 0.16 0.82 ± 0.16 0.118 0.77 ± 0.16 0.82 ± 0.15 0.83 ± 0.17 0.053
eGFR-Cr
(ml · min−1 · 1.73 m−2)b
104.39 ± 26.40 99.89 ± 20.56 96.33 ± 22.21 0.091 102.85 ± 21.48 98.54 ± 22.95 99.19 ± 25.37 0.456
eGFR-Cys C
(ml · min−1 · 1.73 m−2)b
102.53 ± 18.30 96.57 ± 19.84 97.28 ± 19.84 0.102 103.26 ± 19.23 97.17 ± 18.16 95.97 ± 19.53* 0.036
FMD (%)b 8.27 ± 3.77 7.56 ± 3.47 8.08 ± 3.83 0.455 8.07 ± 3.57 8.30 ± 3.87 7.54 ± 3.62 0.413
NO (μmol/L)b 61.62 ± 8.90 59.59 ± 9.61 61.47 ± 9.83 0.322 61.09 ± 9.07 62.55 ± 9.60 59.04 ± 9.49 0.061
ET-1 (pg/ml)b 40.56 ± 6.63 40.44 ± 7.47 42.84 ± 6.99*,** 0.055 40.78 ± 6.77 41.46 ± 6.89 41.60 ± 7.66 0.739
Results are means ± SDs or medians (25th, 75th percentiles) for continuous variables and numbers (percentages) for categorical variables
SD standard deviation, HbA1c hemoglobin A1c, FPG fasting plasma glucose, ACR albumin/creatinine ratio, eGFR-Cr estimated glomerular filtration rate base
on creatinine, eGFR-Cys C estimated glomerular filtration rate base on cystatin C, FMD flow-mediated dilation, NO nitric oxide, ET-1 endothelin-1
acompared using ANOVA with Bonferroni procedure
bcompared using Kruskal-Wallis test
*P < 0.05, as compared to first tertile group in the same classified groups
**P < 0.05, as compared to second tertile group in the same classified groups
Table 3 HbA1c and FPG profiles and severe hypoglycemic episodes during follow-up period
Classified by tertile of SD of HbA1c Classified by tertile of SD of FPG
First tertile
group (n = 79)
Second tertile
group (n = 80)
Third tertile
group (n = 80)
P value First tertile
group (n = 79)
Second tertile
group (n = 80)
Third tertile
group (n = 80)
P value
Mean HbA1c (%) 8.22 ± 1.00 8.33 ± 0.79 8.11 ± 0.56 0.213 8.07 ± 0.65 8.23 ± 0.72 8.35 ± 0.99 0.093
SD of HbA1c (%) 1.41 ± 0.50 2.68 ± 0.36* 3.52 ± 0.47*,** <0.001 2.05 ± 0.92 2.64 ± 0.81* 2.93 ± 0.99* <0.001
CV of HbA1c (%) 17.66 ± 4.59 32.48 ± 3.68* 43.89 ± 4.49*,** <0.001 26.31 ± 9.60 32.21 ± 9.26* 32.75 ± 10.63* <0.001
Mean FPG (mmol/L) 6.98 ± 0.97 6.92 ± 0.86 6.70 ± 0.55 0.075 6.76 ± 0.64 6.83 ± 0.74 7.02 ± 0.98 0.106
SD of FPG (mmol/L) 3.49 ± 1.27 3.70 ± 0.91 4.26 ± 1.24*,** <0.001 2.69 ± 0.48 3.68 ± 0.28* 5.09 ± 0.95*, ** <0.001
CV of FPG (%) 50.10 ± 8.62 53.68 ± 7.80* 63.87 ± 8.27*,** <0.001 39.81 ± 5.34 53.87 ± 6.29* 72.52 ± 8.56*, ** <0.001
Severe hypoglycemic
episodes (times)
0.70 ± 0.64 1.09 ± 0.79* 1.94 ± 1.63*,** <0.001 1.02 ± 1.08 1.32 ± 1.22 1.40 ± 1.33 0.112
Results are means ± SDs
SD standard deviation, CV coefficient of variation, HbA1c hemoglobin A1c, FPG fasting plasma glucose
*P < 0.05, as compared to first tertile group in the same classified groups
**P < 0.05, as compared to second tertile group in the same classified groups
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tertile group were higher than that in third tertile
group (P < 0.05). Increased percentage of NO in first
tertile group was higher than that in second and third
tertile group (P < 0.05). Decreased percentage of ET-1
in first tertile group was greater than that in third ter-
tile groups (P < 0.05).
Renal function and glycemic variability throughout
follow-up period
Changes of renal function and glycemic variability
throughout follow-up are shown in Table 4. In all patients,
eGFR-Cr and eGFR-Cys C were significantly increased,
and ET-1 and ACR were markedly declined at end of
follow-up compared to baseline (P < 0.05).
As with patients grouped by tertile of SD of HbA1c,
eGFR-Cr and eGFR-Cys C were significant increment in
first tertile group (P < 0.05), and were significant decre-
ment in third tertile group (P < 0.05). ACR was significant
decrement in first tertile group (P < 0.05), and significant
increment in third tertile group (P < 0.05). Increased per-
centage of eGFR-Cr and eGFR-Cys C and decreased per-
centage of ACR in first tertile group were significant
greater than those in second and third tertile groups (P <
0.05). Increased percentage of eGFR-Cr and eGFR-Cys C
and decreased percentage of ACR in second tertile group
were greater than those in third tertile groups (P < 0.05).
As with patients grouped by tertile of SD of HbA1c,
decreased percentage of ACR in first tertile group was
significant greater than that in second and third tertile
groups (P < 0.05). Decreased percentage of ACR in sec-
ond tertile group was greater than that in third tertile
groups (P < 0.05).
Correlations of change percentage of brachial FMD, NO,
ET-1, ACR, eGFR-Cr, and eGFR-Cys C throughout follow-up
period with SD of HbA1c, CV of HbA1c, SD of FPG, and CV
of FPG in all patients
We assessed the correlations of change percentage of FMD,
NO, ET-1, ACR, eGFR-Cr, and eGFR-Cys C with SD of
HbA1c (Fig. 2a), CV of HbA1c (Fig. 2b), SD of FPG
(Fig. 3a), and CV of FPG (Fig. 3b) throughout follow-up
period in total participants.
In all patients, change percentage of FMD, NO,
eGFR-Cr, and eGFR-Cys C were remarkable positively,
and change percentage of ET-1 and ACR were signifi-
cant negatively correlated with SD of HbA1c and CV of
HbA1c (P < 0.01, respectively). Similarly, in all patients,
change percentage of FMD, NO, eGFR-Cr, and eGFR-
Cys C were remarkable positively, and change percen-
tage of ET-1 and ACR were significant negatively cor-
related with SD of FPG and CV of FPG (P < 0.01,
respectively).
Change percentage of ACR, eGFR-Cr, and eGFR-Cys C
correlate with change percentage of brachial FMD, NO,
and ET-1 in total patients
We also evaluated the correlations of change percentage
of ACR, eGFR-Cr, and eGFR-Cys C with change percent-
age of brachial FMD, NO, and ET-1 in total patients.
For change percentage of ACR, there was close nega-
tively correlations with change percentage of FMD and
NO, and positively correlation with change percentage
of ET-1 (all P < 0.001). For change percentage of eGFR-
Cr and eGFR-Cys C, there were significant positively
correlations with change percentage of FMD and NO,
Table 4 Changes of FMD, NO, ET-1, ACR, eGFR-Cr, and eGFR-Cys C throughout follow-up period
Total
(n = 239)
Classified by tertile of SD of HbA1c Classified by tertile of SD of FPG
First tertile
group (n = 79)
Second tertile
group (n = 80)
Third tertile
group (n = 80)
P value First tertile
group (n = 79)
Second tertile
group (n = 80)
Third tertile


























































2.73 ± 6.43 7.49 ± 5.94 1.94 ± 5.35* −1.24 ± 4.65*,** <0.001 3.74 ± 5.90 2.83 ± 6.24 1.61 ± 7.00 0.101
Change percentage
of eGFR-Cys C (%)b
2.35 ± 5.84 6.64 ± 5.37 1.66 ± 4.89* −1.25 ± 4.24*,** <0.001 3.26 ± 5.34 2.47 ± 5.66 1.32 ± 6.36 0.097
Results are means ± SDs or medians (25th, 75th percentiles)
acompared using ANOVA with Bonferroni procedure
bcompared using Kruskal-Wallis test
*P < 0.05, vs. first tertile group
**P < 0.05, vs. second tertile group
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and negatively correlation with change percentage of
ET-1 (all P < 0.001).
Multiple regression analysis
Backward stepwise procedure of multiple linear regres-
sion analysis was performed to determine factors inde-
pendently related to changes of endothelial function and
renal function (Table 5). The change percentage of
FMD, NO, ET-1, ACR, eGFR-Cr, and eGFR-Cys C was
used as dependent variables, respectively.
Independent variables included SDs of HbA1c and
FPG, age, sex, current smoking, current drinking, dur-
ation of diabetes, BMI, baseline blood press, baseline
blood lipids, baseline HbA1c, baseline FPG, mean
HbA1c and FPG during follow-up, and episodes of se-
vere hypoglycemia over follow-up period. For change
percentage of FMD, there were statistically significant
results for SD of HbA1c, SD of FPG, mean HbA1c,
baseline SBP, smoking, and baseline LDL-c. For change
percentage of NO, there were statistically significant
results for SD of HbA1c, SD of FPG, and mean FPG.
For change percentage of ET-1, there were statistically
significant results for SD of HbA1c, SD of FPG, smo-
king, and baseline TCHO. For change percentage of
ACR, there were statistically significant results for SD
of HbA1c, SD of FPG, mean HbA1c, mean FPG, and
smoking. For change percentage of eGFR-Cr, there
were significant results for SD of HbA1c, SD of FPG,
mean HbA1c, baseline SBP, and smoking. For change
percentage of eGFR-Cys C, there were significant re-
sults for SD of HbA1c, SD of FPG, mean HbA1c, mean
FPG, smoking, and baseline TCHO.
Independent variables included CVs of HbA1c and
FPG, age, sex, current smoking, current drinking, dur-
ation of diabetes, BMI, baseline blood press, baseline
blood lipids, baseline HbA1c, baseline FPG, mean
HbA1c and FPG during follow-up, and episodes of se-
vere hypoglycemia over follow-up period. For change
percentage of FMD, there were statistically significant
results for CV of HbA1c, CV of FPG, baseline SBP, and
baseline TCHO. For change percentage of NO, there
were statistically significant results for CV of HbA1c,
CV of FPG, and mean FPG. For change percentage of
ET-1, there were statistically significant results for CV
of HbA1c, CV of FPG, baseline TCHO, and baseline
HDL-c. For change percentage of ACR, there were sta-
tistically significant results for CV of HbA1c, CV of
FPG, mean FPG, and baseline SBP. For change percentage
of eGFR-Cr, there were significant results for CV of
HbA1c, CV of FPG, and mean FPG. For change percen-
tage of eGFR-Cys C, there were significant results for CV
of HbA1c, CV of FPG, mean HbA1c, and mean FPG.
Importantly, from the results of the backward stepwise
regression analysis, only SDs of HbA1c and FPG and
CVs of HbA1c and FPG were always statistically and
independently correlated with change percentage of
FMD, NO, ET-1, ACR, eGFR-Cr, and eGFR-Cys C.
Discussion
This is the first study to explore the association of long-
term GV, using both visit-to-visit variabilities of HbA1c
and FPG, with the progression of endothelial and renal
dysfunction in patients with T2DM. Results of our study
demonstrated those (1) excessive visit-to-visit GV asso-
ciated endothelial dysfunction and renal dysfunction;
(2) visit-to-visit GV was statistically correlated with the
progression of endothelial dysfunction and renal dys-
function independent of mean HbA1c and FPG, (3)
progression of renal dysfunction significant correlated
with progression of endothelial dysfunction in T2DM
patients.
Effective glycemic control is a critical goal of diabetes
management to reduce the risk of diabetic complications
[13, 14]. In our study, both endothelial function and
renal function were improved along with the decline
in HbA1c and FPG during follow-up in patients with
T2DM.
However, accumulating evidences demonstrated that
there was an independent association between higher
variability in glycemic control and worsened outcomes
in patients with diabetes [12, 32, 33]. Long-term fluctua-
tions in glycemia, in contrast to short-term glucose in-
stability, contribute to the development of microvascular
complications in type 1 diabetes [33]. Kilpatrick and col-
leagues [33] reported that excessive long-term variability
in HbA1c adds to the mean value in predicting diabetic
nephropathy and retinopathy. In the observational
Finnish Diabetic Nephropathy (FinnDiane) Study [34],
GV (assessed by SD of serial measurements of A1c
from baseline to follow-up) predicts the development
and progression of incipient and overt renal disease in
T1DM patients. In T2DM patients, long-term variability
in HbA1c is independently associated with the develop-
ment of microalbuminuria [35].
(See figure on previous page.)
Fig. 2 Correlations of SD of HbA1c and CV of HbA1c with change percentage of brachial FMD, NO, ET-1, eGFR-Cr, eGFR-Cys C, and ACR throughout
follow-up period. SD of HbA1c was positively correlated with change percentage of ET-1 and ACR, and negatively correlated with change percentage
of brachial FMD, NO, eGFR-Cr and eGFR-Cys C (a). CV of HbA1c was positively correlated with change percentage of ET-1 and ACR, and negatively
correlated with change percentage of brachial FMD, NO, eGFR-Cr and eGFR-Cys C (b)
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In consistent with previous studies, at least to some
extent, our results revealed that excessive visit-to-visit
GV was not only closely associated with the progression
of renal dysfunction, but also associated with the
progression of endothelial dysfunction independent of
mean HbA1c and FPG. Brachial FMD, NO, eGFR-Cr
and eGFR-Cys C increased, and ET-1 and ACR declined
in first tertile GV group, which classified by tertile of SD
of either HbA1c or FPG. On the contrary, brachial FMD,
NO, eGFR-Cr and eGFR-Cys C declined, and ET-1 and
ACR increased in third tertile GV group. Excessive visit-
to-visit GV may be an important risk factor of progres-
sion of endothelial dysfunction and renal dysfunction in
T2DM patients.
HbA1c, which reflects the 2-to-3 month average en-
dogenous exposure to glucose including postprandial
spikes in the blood glucose level and has low intraindi-
vidual variability, have become established parameter of
long-term glycemic control in diabetics [36]. For this
purpose, several analytical methods have been devel-
oped. In the present study, HbA1c was evaluated using
the DCA 2000 instrument. The DCA 2000 instrument,
base on an immunochemical technique, has been pro-
posed for the rapid and simple evaluation of HbA1c.
The accuracy and reproducibility of this HbA1c measure-
ment has been certificated and used in clinical practice, as
revealed by its good precision and good agreement with
the reference system (Diamat™ using high performance
liquid chromatography method) [17, 18].
SD is a widely used method to assess variability, al-
though it is a measure of dispersion rather than a meas-
ure of GV [37]. SD has been shown a linear relationship
with mean glucose. When SD is corrected for the mean
and CV is obtained, the linear relationship is largely dis-
appeared [37]. However, Buscemi and colleagues [38, 39]
evaluated GV using CV measured by continuous glucose
monitoring. They found that CV of glucose was closely
related to endothelial dysfunction and atherosclerosis
even in non-diabetic subjects. Variability was evaluated
by both SD and CV in the present study. Our results
agreed with DeVries [37] and there were some differences
with Buscemi [38, 39]. Reason of the differences between
our study and Buscemi’s may be as follows: Buscemi’s
assessed short-time GV using continuous glucose moni-
toring, yet we evaluated visit-to-visit GV.
As endothelial dysfunction is a systemic disorder [40],
it is deemed that endothelial dysfunction plays a crucial
role in the pathogenesis of diabetic nephropathy [41]. On
the other hand, renal dysfunction is regarded to be an
important factor in causing endothelial dysfunction in
the systemic vasculature [42, 43]. In the present study,
changes of endothelial function strongly related to changes
of renal function. However, it was unclear whether change
of renal function was a cause or a consequence of change
of endothelial function.
Episode of severe hypoglycaemia is a common side ef-
fect of hypoglycemic therapy in patients with T2DM and
presents a barrier to achieving optimal diabetes manage-
ment [44]. Hypoglycemia not only can impact patient
quality of life, but also is regarded as a contributor to
renal dysfunction, cardiovascular events and mortality
[44, 45]. Evidences had shown that excessive GV in on-
treated patients with diabetes implies that there were
more hypoglycemic and/or hyperglycemic episodes,
although the average HbA1c levels are desirable [35]. In
the present study, we observed that episodes of severe
hypoglycemia in higher SD of HbA1c groups were more
than those in lower SD of HbA1c groups. With regard
to the differences in episodes of severe hypoglycemia
among three groups, it is possible affecting the relation-
ship between GV and the progression of endothelial and
renal dysfunction in patients with T2DM. However, GV
was still significantly associated with the progression of
endothelial and renal dysfunction in patients after ad-
justed episodes of severe hypoglycemia.
Yet, there were several limitations that need to be
addressed to our study. First, only a small number of
subjects were enrolled in our study. Large-scale and
multicenter prospective investigations are needed in
the future. Second, as above described, it was unclear
of association between change of renal function and
change of endothelial function. It needs further study,
even in vitro, in the future to clarify the association.
Third, 25 patients exclusion from the analyses might
have introduced a bias in this study.
Conclusions
In conclusion, our study documents that excessive
visit-to-visit GV is associated with the progression of
endothelial and renal dysfunction in patients with T2DM.
Controlling excessive visit-to-visit GV may be an impor-
tant factor to improve endothelial and renal function in
management and treatment of patients with T2DM.
(See figure on previous page.)
Fig. 3 Correlations of SD of FPG and CV of FPG with change percentage of brachial FMD, NO, ET-1, eGFR-Cr, eGFR-Cys C, and ACR throughout
follow-up period. SD of FPG was positively correlated with change percentage of ET-1 and ACR, and negatively correlated with change percentage
of brachial FMD, NO, eGFR-Cr and eGFR-Cys C (a). CV of FPG was positively correlated with change percentage of ET-1 and ACR, and negatively
correlated with change percentage of brachial FMD, NO, eGFR-Cr and eGFR-Cys C (b)
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5A. SDs of HbA1c and FPG are included in independent variables in models




























<0.001 – – – – 0.789
(0.006, 1.572)
0.002 – – −0.925
(−1.672, −0.178)
0.022
Mean FPG – – −2.306
(−4.294, −0.318)
0.005 – – 1.524
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5B. CVs of HbA1c and FPG are included in independent variables in models


























Mean HbA1c – – – – – – – – – – −0.873
(−1.716, −0.030)
0.034
Mean FPG – – −1.045
(−1.902, −0.178)









0.040 – – – – 0.121
(0.022, 0.219)
0.017 – – – –
Baseline TCHO −0.511
(−1.019, −0.002)
0.049 – – 0.676
(0.045, 1.306)
0.036 – – – – – –
Baseline HDL-c – – – – −1.139
(−2.229, −0.049)
0.043 – – – – – –
Independent variables include age, sex, current smoking, current drinking, duration of diabetes, body mass index, baseline blood press, baseline blood lipids, baseline fasting plasma glucose, baseline HbA1c,
mean fasting plasma glucose and HbA1c during follow-up, standard deviation of fasting plasma glucose and HbA1c during follow-up, coefficient of variation of fasting plasma glucose and HbA1c during follow-up,
and episodes of severe hypoglycemia over follow-up period
ACR albumin/creatinine ratio, eGFR-Cr estimated glomerular filtration rate based on creatinine, eGFR-Cys C estimated glomerular filtration rate based on cystatin C, TCHO total cholesterol, DBP diastolic blood pressure,
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